
Antibacterial Agents Chemistry, Mode of Action, Mechanisms of Resistance and Clinical Applications
by Anderson, Rosaleen; Groundwater, Paul W.; Todd, Adam; Worsley, Alan-
This Item Qualifies for Free Shipping!*
*Excludes marketplace orders.
Buy New
Rent Textbook
Used Textbook
We're Sorry
Sold Out
eTextbook
We're Sorry
Not Available
How Marketplace Works:
- This item is offered by an independent seller and not shipped from our warehouse
- Item details like edition and cover design may differ from our description; see seller's comments before ordering.
- Sellers much confirm and ship within two business days; otherwise, the order will be cancelled and refunded.
- Marketplace purchases cannot be returned to eCampus.com. Contact the seller directly for inquiries; if no response within two days, contact customer service.
- Additional shipping costs apply to Marketplace purchases. Review shipping costs at checkout.
Summary
Author Biography
Professor Paul Groundwater, Professor of Medicinal Chemistry, Faculty of Pharmacy, The University of Sydney, Australia
Dr Adam Todd, Senior Lecturer in Pharmacy Practice, Sunderland Pharmacy School, University of Sunderland, UK
Dr Alan Worsley, Principal Lecturer in Pharmacy Practice, Sunderland Pharmacy School, University of Sunderland, UK
Table of Contents
Preface | p. xi |
Introduction To Microorganisms And Antibacterial Chemotherapy | p. 1 |
Microorganisms | p. 3 |
Key points | p. 3 |
Classification | p. 3 |
Structure | p. 4 |
Bacterial detection and identification | p. 17 |
Other than its mode of action, what factors determine the antibacterial activity of a drug? | p. 25 |
Bacterial resistance | p. 27 |
The âÇ post-antibiotic ageâÇÖ? | p. 29 |
References | p. 31 |
Questions | p. 33 |
Agents Targeting Dna | p. 35 |
Quinolone antibacterial agents | p. 37 |
Key points | p. 37 |
Discovery | p. 37 |
Synthesis | p. 39 |
Bioavailability | p. 41 |
Mode of action and selectivity | p. 44 |
Bacterial resistance | p. 45 |
Clinical applications | p. 47 |
Adverse drug reactions | p. 50 |
Drug interactions | p. 55 |
Recent developments | p. 56 |
References | p. 60 |
Rifamycin antibacterial agents | p. 63 |
Key points | p. 63 |
Discovery | p. 63 |
Synthesis | p. 65 |
Bioavailability | p. 68 |
Mode of action and selectivity | p. 69 |
Bacterial resistance | p. 71 |
Clinical applications | p. 71 |
Adverse drug reactions | p. 77 |
Drug interactions | p. 78 |
Recent developments | p. 81 |
References | p. 81 |
Nitroimidazole antibacterial agents | p. 85 |
Key points | p. 85 |
Discovery | p. 85 |
Synthesis | p. 86 |
Bioavailability | p. 86 |
Mode of action and selectivity | p. 87 |
Mechanisms of resistance | p. 89 |
Clinical applications | p. 90 |
Adverse drug reactions and contraindications | p. 94 |
Drug interactions | p. 95 |
Recent developments | p. 97 |
References | p. 97 |
Questions | p. 101 |
Agents Targeting Metabolic Processes | p. 103 |
Sulfonamide antibacterial agents | p. 105 |
Key points | p. 105 |
Discovery | p. 105 |
Synthesis | p. 107 |
Bioavailability | p. 108 |
Mode of action and selectivity | p. 111 |
Bacterial resistance | p. 114 |
Clinical applications | p. 115 |
Adverse drug reactions | p. 119 |
Drug interactions | p. 122 |
Recent developments | p. 123 |
References | p. 124 |
Trimethoprim | p. 127 |
Key points | p. 127 |
Discovery | p. 127 |
Synthesis | p. 128 |
Bioavailability | p. 130 |
Mode of action and selectivity | p. 130 |
Bacterial resistance | p. 136 |
Clinical applications | p. 136 |
Adverse drug reactions | p. 138 |
Drug interactions | p. 138 |
Recent developments | p. 139 |
References | p. 140 |
Questions | p. 145 |
Agents Targeting Protein Synthesis | p. 147 |
Aminoglycoside antibiotics | p. 149 |
Key points | p. 149 |
Discovery | p. 149 |
Synthesis | p. 152 |
Bioavailability | p. 156 |
Mode of action and selectivity | p. 158 |
Bacterial resistance | p. 160 |
Clinical applications | p. 161 |
Adverse drug reactions | p. 165 |
Drug interactions | p. 167 |
Recent developments | p. 168 |
References | p. 168 |
Macrolide antibiotics | p. 173 |
Key points | p. 173 |
Discovery | p. 173 |
Synthesis | p. 175 |
Bioavailability | p. 177 |
Mode of action and selectivity | p. 180 |
Bacterial resistance | p. 181 |
Clinical applications | p. 182 |
Adverse drug reactions | p. 187 |
Drug interactions | p. 189 |
Recent developments | p. 192 |
References | p. 193 |
Tetracycline antibiotics | p. 197 |
Key points | p. 197 |
Discovery | p. 197 |
Synthesis | p. 200 |
Bioavailability (agwuh and macgowan, 2006) | p. 205 |
Mode of action and selectivity | p. 210 |
Bacterial resistance | p. 213 |
Clinical applications | p. 217 |
Adverse drug reactions | p. 223 |
Drug interactions | p. 224 |
Recent developments | p. 224 |
References | p. 225 |
Chloramphenicol | p. 231 |
Key points | p. 231 |
Discovery | p. 231 |
Synthesis | p. 231 |
Bioavailability | p. 232 |
Mode of action and selectivity | p. 235 |
Bacterial resistance | p. 235 |
Clinical applications | p. 236 |
Adverse drug reactions | p. 238 |
Drug interactions | p. 239 |
Recent developments | p. 239 |
References | p. 241 |
Oxazolidinones | p. 243 |
Key points | p. 243 |
Discovery | p. 243 |
Synthesis | p. 245 |
Bioavailability | p. 247 |
Mode of action and selectivity | p. 248 |
Bacterial resistance | p. 249 |
Clinical applications | p. 251 |
Adverse drug reactions | p. 252 |
Drug interactions | p. 253 |
Recent developments | p. 254 |
References | p. 254 |
Questions | p. 259 |
Agents Targeting Cell-Wall Synthesis | p. 261 |
b-lactam antibiotics | p. 263 |
Key points | p. 263 |
Discovery | p. 263 |
Synthesis | p. 272 |
Bioavailability | p. 277 |
Mode of action and selectivity | p. 284 |
Bacterial resistance | p. 285 |
Clinical applications | p. 290 |
Adverse drug reactions | p. 296 |
Drug interactions | p. 298 |
Recent developments | p. 300 |
References | p. 301 |
Glycopeptide antibiotics | p. 305 |
Discovery | p. 305 |
Synthesis | p. 305 |
Bioavailability | p. 307 |
Mode of action and selectivity | p. 308 |
Bacterial resistance | p. 311 |
Clinical applications | p. 313 |
Adverse drug reactions | p. 314 |
Drug interactions | p. 315 |
Recent developments | p. 316 |
References | p. 317 |
Cycloserine | p. 319 |
Key points | p. 319 |
Discovery | p. 319 |
Synthesis | p. 319 |
Bioavailability | p. 320 |
Mode of action and selectivity | p. 321 |
Bacterial resistance | p. 323 |
Clinical applications | p. 323 |
Adverse drug reactions and contraindications | p. 325 |
Drug interactions | p. 325 |
Recent developments | p. 325 |
References | p. 325 |
Isoniazid | p. 327 |
Key points | p. 327 |
Discovery | p. 327 |
Synthesis | p. 328 |
Bioavailability | p. 329 |
Mode of action and selectivity | p. 329 |
Bacterial resistance | p. 330 |
Clinical applications | p. 331 |
Adverse drug reactions and contraindications | p. 333 |
Drug interactions | p. 334 |
Recent developments | p. 335 |
References | p. 335 |
Daptomycin | p. 339 |
Key points | p. 339 |
Discovery | p. 339 |
Synthesis | p. 340 |
Bioavailability | p. 341 |
Mode of action and selectivity | p. 341 |
Bacterial resistance | p. 343 |
Clinical applications | p. 343 |
Adverse drug reactions and contraindications | p. 344 |
Recent developments | p. 345 |
References | p. 346 |
Questions | p. 349 |
Index | p. 351 |
Table of Contents provided by Publisher. All Rights Reserved. |
An electronic version of this book is available through VitalSource.
This book is viewable on PC, Mac, iPhone, iPad, iPod Touch, and most smartphones.
By purchasing, you will be able to view this book online, as well as download it, for the chosen number of days.
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.
A downloadable version of this book is available through the eCampus Reader or compatible Adobe readers.
Applications are available on iOS, Android, PC, Mac, and Windows Mobile platforms.
Please view the compatibility matrix prior to purchase.